Oculis Holding AG Company Profile
NASDAQ: OCSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:29 AM ET
Oculis at a glance
Oculis Holding AG (NASDAQ: OCS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Zug, Switzerland. Oculis is led by Dr. Riad Sherif M.B.A., M.D. and employs about 60 people. At a market capitalization of $523.5 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001953530, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Oculis do?
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Business description based on the company's public filings.
Company information
- Legal name
- Oculis Holding AG
- Ticker
- NASDAQ: OCS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Riad Sherif M.B.A., M.D.
- Employees
- 60
- Headquarters
- Bahnhofstrasse 20, Zug, Switzerland
- Phone
- 41 41 711 3960
- Website
- oculis.com
- Market cap
- $523.50M
- SEC CIK
- 0001953530
Companies similar to Oculis
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BLSMBlossomHill Therapeutics Inc. | 16.34 | -1.66% | $519.21M | vs OCS |
| ACRSAclaris Therapeutics Inc. | 3.48 | +2.35% | $512.25M | vs OCS |
| CTMXCytomX Therapeutics Inc. | 2.46 | -3.53% | $536.03M | vs OCS |
| NGNENeurogene Inc. | 26.91 | +4.02% | $538.51M | vs OCS |
| EVOEvotec SE ADR | 1.53 | -4.94% | $543.89M | vs OCS |
| CBIOCrescent Biopharma Inc. | 13.52 | +0.22% | $502.23M | vs OCS |
| MPLTMapLight Therapeutics Inc. | 9.03 | -3.53% | $501.85M | vs OCS |
| PBYIPuma Biotechnology Inc | 9.70 | -1.17% | $500.46M | vs OCS |